The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Will The Market Size Of The mRNA Therapeutics CDMO Market Evolve From 2026 To 2030?
The mrna therapeutics cdmo market size has expanded significantly in recent years. It is projected to increase from $4.74 billion in 2025 to $5.31 billion in 2026, registering a compound annual growth rate (CAGR) of 12.0%. The historical period’s growth can be attributed to factors such as the limited availability of specialized mrna cdmo services, a reliance on in-house pharmaceutical manufacturing, the rise in infectious disease outbreaks, the adoption of early-stage analytical testing, and the expansion of academic and research collaborations.
The mrna therapeutics cdmo market is projected to experience substantial expansion in the coming years. This market is set to reach $8.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 11.7%. Key drivers for this growth during the forecast period include increased investment in mrna therapeutic development, innovations in plasmid dna and mrna synthesis technologies, the expansion of cancer immunotherapy and protein replacement treatments, a rising need for fill-finish operations, and the proliferation of collaborations between biotech firms and CDMOs. Significant trends anticipated in the same period involve a heightened demand for outsourced mrna development and production, a greater emphasis on lipid nanoparticle (lnp) formulation techniques, the enlargement of viral vaccine and cancer immunotherapy pipelines, strengthened regulatory adherence and quality control protocols, and the increasing utilization of analytical and bioanalytical laboratory services.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25841&type=smp
What Key Drivers Are Influencing The Growth Of The mRNA Therapeutics CDMO Market?
The increasing prevalence of chronic and infectious diseases is anticipated to drive the expansion of the mRNA therapeutics CDMO market in the future. These diseases include persistent health issues like diabetes, cardiovascular disorders, and asthma, alongside illnesses stemming from pathogenic agents such as viruses, bacteria, and parasites, capable of transmission between people, either directly or indirectly. The rise in chronic and infectious diseases is linked to aging populations, who are generally more vulnerable to both enduring conditions and infections. The mRNA therapeutics CDMO plays a role in tackling chronic and infectious diseases by offering comprehensive development and manufacturing services, thus speeding up the provision of specific and individualized mRNA therapies to patients. For example, the World Health Organization, an international public health body based in Switzerland, reported in October 2024 that around 8.2 million individuals received a new tuberculosis diagnosis in 2023, an increase from approximately 7.5 million in 2022, underscoring the increasing worldwide impact of infectious diseases. Consequently, the escalating burden posed by chronic and infectious diseases is a primary factor fueling the expansion of the mRNA therapeutics CDMO market.
Which Segment Areas Are Covered In The mRNA Therapeutics CDMO Market Analysis?
The mrna therapeutics cdmo market covered in this report is segmented –
1) By Type Of Service: Development Services, Manufacturing Services, Laboratory Services
2) By Indication: Infectious Diseases, Metabolic And Genetic Diseases, Cardiovascular And Cerebrovascular Diseases
3) By Application: Viral Vaccines, Protein Replacement Therapies, Cancer Immunotherapies
4) By End User: Pharmaceutical Companies, Biotechnology Companies, Academic Institutions, Research Organizations
Subsegments:
1) By Development Services: Process Development, Analytical Method Development, Formulation Development, Regulatory Support
2) By Manufacturing Services: Plasmid DNA Manufacturing, mRNA Synthesis, Lipid Nanoparticle (LNP) Formulation, Fill-Finish Services
3) By Laboratory Services: Quality Control Testing, Stability Testing, Bioanalytical Testing, Preclinical Testing
What Key Developments And Trends Are Impacting The mRNA Therapeutics CDMO Market?
Leading firms within the mRNA therapeutics CDMO market are concentrating on devising cutting-edge solutions, exemplified by in situ nanomedicine vaccines, to boost the efficacy and accuracy of mRNA-based vaccines through focused immune stimulation. An in situ nanomedicine vaccine represents a subsequent generation mRNA-based therapeutic crafted to produce nanomedicines directly within a patient’s system, facilitating targeted administration and bespoke immune activation via engineered transgene expression. As an illustration, Esphera SynBio Inc., a biotechnology firm located in Canada, initiated a new project in January 2025, supported by the CQDM Quantum Leap program. This endeavor is designed to improve first-generation lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines by integrating proprietary transgene designs that prompt the in vivo generation of immunostimulatory nanomedicines. Such an approach allows for exact antigen delivery and customized immune responses, thereby positioning this technology as a prospective advancement in vaccine innovation.
Which Global Companies Are Actively Competing In The mRNA Therapeutics CDMO Market?
Major companies operating in the mrna therapeutics cdmo market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG.
Read the full mrna therapeutics cdmo market report here:
https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-cdmo-global-market-report
Which Region Is Expected To Register The Fastest Growth In The mRNA Therapeutics CDMO Market?
North America was the largest region in the mRNA therapeutics CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored mRNA Therapeutics CDMO Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25841&type=smp
Browse Through More Reports Similar to the Global mRNA Therapeutics CDMO Market 2026, By The Business Research Company
Mrna Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/mrna-therapeutics-global-market-report
Mrna Cancer Vaccines And Therapeutics Market Report 2026
Peptide And Oligonucleotide Cdmo Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
